Finanzen von Agomab Therapeutics NV (AGMB)AGMBAgomab Therapeutics NV

In the context of the broader market, AGMB competes directly with industry leaders such as DMAC and PROK. With a market capitalization of $448.65M, it holds a significant position in the sector. When comparing efficiency, AGMB's gross margin of N/A stands against DMAC's N/A and PROK's 100.00%. Such benchmarking helps identify whether Agomab Therapeutics NV is trading at a premium or discount relative to its financial performance.

Agomab's financial performance shows a negative net income of -11.73 million EUR for Q4 2024, with a forward P/E ratio of 0, indicating no earnings expected in the near term. The current ratio is strong at 13.99, suggesting good liquidity, but the company is still operating at a loss.